arrow
S

Stephen J. Pettitt

Institute of Cancer Research
H指数:31
被引数:5,626

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

PUM3 is an essential suppressor of replication stress in homologous recombination deficient breast cancer

PUM3是同源重组缺陷型乳腺癌中复制应激所必需的抑制因子

2026-09-210
OAAI
The anion channel GPR89 is a tumor-specific dependency in breast cancer

GPR89阴离子通道是乳腺癌的肿瘤特异性依赖

2026-08-240
OA
Tumour specific HORMAD1 expression perturbs mitotic arrest and drives sensitivity to mitotic kinase inhibitors

肿瘤特异性HORMAD1表达扰乱有丝分裂停滞并驱动对有丝分裂激酶抑制剂的敏感性

2026-03-110
OAAI
Correction to: Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells

更正:APOBEC3B表达升高驱动一种 kataegic-like 突变特征和与复制应激相关的治疗易损性,发生在p53缺陷细胞中。

2026-02-160
PRE
NASP modulates histone turnover to drive PARP inhibitor resistance

NASP通过调节组蛋白周转来驱动PARP抑制剂耐药性。

Nature
IF48.5
2025-08-130
PRE
The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models

PARP抑制剂talazoparib与呼肠孤病毒协同作用,在小鼠模型中体内诱导癌症杀伤和肿瘤控制

2025-07-080
OAAI
CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13
2024-10-010
OAAI
CDK12 loss promotes prostate cancer development while exposing vulnerabilities to paralog-based synthetic lethality
2024-06-100
PRE
Functional assessment of RAD51 foci and replication fork dynamics in PARPi resistant BRCA1/2 mutated breast cancer
2024-05-020
PRE
Longitudinal pro fi ling identi fi es co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer
2024-04-0113
OA
MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells

MND1和PSMC3IP控制有丝分裂细胞的PARP抑制剂敏感性

2023-05-013
OA
Longitudinal analysis of PARP inhibitor and platinum resistance in BRCA1/2m breast cancer using liquid biopsy
2023-04-043
PRE
SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
2022-10-237
OAAI